Seeking Alpha

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular to Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ: OCUL, “Ocular”, the ...

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...
Healio

Ocular Therapeutix receives FDA nod for SOL-R registrational study of Axpaxli

Please provide your email address to receive an email when new articles are posted on . Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory ...
Business Insider

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data ...

Excellent enrollment in AXPAXLI SOL-1 study (Phase 3, wet AMD) with 60 study sites active and 151 subjects enrolled in various stages of loading and randomization as of June 7, 2024, reflecting strong ...
Nasdaq

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through ...